Seres and Pfizer are also set for upcoming FDA Pdufa decisions, and a panel is scheduled for Astrazeneca and Merck’s Lynparza.
The chocolate-to-vitamins giant discovers that launching a drug is hard. Should its biopharma partners be worried?
Following the Pfizer-Biohaven blueprint, could other licensing deals turn into buyouts?
With Ferring filed and Seres preparing to do so, regulators' views on microbiome approaches to C difficile will soon be heard.
The UK company insists that by the end of the year a partner will have been found for its microbiome project to prevent C difficile infections.
A strong performance from a handful of large drug developers could not rescue the sector from a weak three months on the stock market.